HUMA — Humacyte, Inc.
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 218
- Website: https://www.humacyte.com
Latest SEC filings for HUMA
- 3 — 2026-09-28
- 10-Q — 2026-08-12
- 8-K — 2026-08-12
- 8-K — 2026-07-31
- 8-K — 2026-06-11
- 424B5 — 2026-06-11
- 8-K — 2026-06-10
- 424B5 — 2026-06-10
- 8-K — 2026-06-09
- 8-K — 2026-06-05
Latest HUMA news
- — Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today (Zacks Investment Research)
- — Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks Investment Research)
- — Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks Investment Research)
- — Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know (zacks.com)
- — Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks Investment Research)
- — Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade (zacks.com)
- — Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks Investment Research)
- — Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note (zacks.com)
- — Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik (globenewswire.com)
- — Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why (zacks.com)
Educational tool only — not investment advice.